A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

Bryostatin 1 is a novel antitumour agent derived from Bugula neritina of the marine phylum Ectoprocta. Nineteen patients with advanced solid tumours were entered into a phase I study to evaluate the toxicity and biological effects of bryostatin 1. Bryostatin 1 was given as a one hour intravenous inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Testa, N., Stern, P., McDermott, R., Potter, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968558/
https://www.ncbi.nlm.nih.gov/pubmed/8347500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968558/
https://www.ncbi.nlm.nih.gov/pubmed/8347500

Ejemplares similares